•   
  •   
  •   

Politics Johnson & Johnson: 'Insufficient' evidence of 'causal relationship' between COVID-19 vaccine, blood clots

22:50  16 april  2021
22:50  16 april  2021 Source:   thehill.com

Food banks, passing on passports, governors’ shots: News from around our 50 states

  Food banks, passing on passports, governors’ shots: News from around our 50 states How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.

Johnson & Johnson scientists said on Friday that there's currently "insufficient" evidence of a "causal relationship" between the company's COVID-19 vaccine and the rare cases of blood clots that prompted a pause in distribution.

a close up of a sign: Johnson & Johnson building © Getty Images Johnson & Johnson building

Company researchers wrote a letter to the editor of The New England Journal of Medicine published Friday that said "at this time, evidence is insufficient to establish a causal relationship between these events" and the Johnson & Johnson vaccine.

The vaccine manufacturer's comments follow the Tuesday decision by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) to call for a pause in the rollout of Johnson & Johnson's vaccine amid six blood clot cases. Every state has since suspended Johnson & Johnson vaccinations, and the company has halted clinical trials.

Immigrant aid, lifeguard shortage, Frontier Days: News from around our 50 states

  Immigrant aid, lifeguard shortage, Frontier Days: News from around our 50 states How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.

The six documented cases, out of the more than 6.8 million that received the Johnson & Johnson vaccine in the U.S., involved cerebral venous sinus thrombosis (CVST) and low blood-platelet counts, leading to one death.

"CVST is a very rare health condition, and thus far, events reported in recipients of the ... vaccine are occurring within the range of published background incidence," the researchers wrote. "It is important to note that the incidence of CVST associated with low platelets is unknown and is considered by the FDA and the CDC to be extremely low."

"We continue to work closely with experts and regulators to assess the data, and we support the open communication of this information to health care professionals and the public," the researchers concluded.

Federal health agencies recommend pause of J&J vaccine after 'extremely rare' blood clots

  Federal health agencies recommend pause of J&J vaccine after 'extremely rare' blood clots Some 6.8 million have received the vaccine in the United States. Of these six have experienced the clot, the FDA and CDC said.The Food and Drug Administration and the Centers for Disease Control and Prevention issued a statement saying they were "recommending a pause in the use of this vaccine out of an abundance of caution.

Johnson & Johnson noted that out of more than 75,000 participants in the clinical trial program for its vaccine, one case of CVST emerged, prompting the manufacturer to pause the program to review the case. When "no clear causality was established," Johnson & Johnson continued with the trial with permission from the data and safety monitoring board.

Following this week's pause, an independent advisory panel at the CDC delayed voting to make a recommendation on the vaccine in question in order to gather more evidence on the rare cases.

The CDC's Advisory Committee on Immunization Practices intends to meet on April 23 to provide guidance on Johnson & Johnson's vaccine.

Some cases involving recipients of the AstraZeneca vaccine, which is approved for use in Europe, developing rare blood clots have also emerged in recent weeks.

Both the AstraZeneca and Johnson & Johnson vaccines are adenovirus-based, but Johnson & Johnson scientists said the vectors and protein inserts used in each shot are "substantially different."

Concerns have grown over whether the delay for the Johnson & Johnson vaccine will impact vaccine confidence and hesitancy across the country.

Scientists exploring possible link between J&J, AstraZeneca vaccine blood clot issues .
Similarities between Johnson & Johnson and AstraZeneca blood clot issues have scientists exploring possible linkDoctors, scientists and public health experts are turning to Europe for clues, where a similar vaccine made by AstraZeneca -- not yet authorized in the U.S. -- also has been linked to a number of rare blood clots.

usr: 0
This is interesting!